UNSPSC 51131908: Hetastarch

This classification denotes a blood substitute, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 875Y4127EA. European Medicines Agency schedules Hetastarch in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14097MIG. Hetastarch generally arises in the molecular formula (C6H7O5)N.C2H5O.H. The term 'hetastarch' is an FDA designation. As of Q4 2014, HETASTARCH remains the US FDA Preferred Term for this commodity. Hetastarch bears US NLM identifiers UMLS ID C0020352 and NCI Concept Code C559.

SMILES: CC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)OC)O)O)OC4C(C(C(C(O4)CO)OC)O)OCCO)O)O)O)O.

UNSPSC 51131908 Hetastarch is a Commodity code covering synthetic colloid plasma volume expanders used in acute medical care and trauma response. State and local governments—primarily health departments, public hospital systems, emergency medical services agencies, and correctional health programs—procure hetastarch solutions as critical inventory for emergency departments, operating rooms, and field response units. The product appears in both routine procurement cycles for standing inventory and urgent replenishment buys following mass-casualty events or seasonal demand surges. Issuing bodies span state health authorities, county hospital districts, municipal EMS agencies, and independent healthcare authorities operating public medical facilities.

The source provided contains no recent state and local contract opportunities tagged to this code. Without posted solicitations, issuing-body concentration, geographic activity, and representative recent RFPs or RFQs cannot be characterized. When hetastarch does appear in state and local procurement, it typically moves through health-system cooperative purchasing agreements or direct-award medical-supply contracts rather than open competitive notices, which may limit visibility in public opportunity databases. Firms pursuing this code should monitor state health department procurement channels and regional hospital collaborative purchasing networks for volume commitments and standing-order opportunities.